Health Care https://www.benzinga.com/views/taxonomy/term/140295 en The Week Ahead In Biotech: Spotlight On ESMO Conference https://www.benzinga.com/general/biotech/19/09/14460216/the-week-ahead-in-biotech-spotlight-on-esmo-conference <p>Biotech stocks put up a muted performance in the week ended Sept. 20 amid conference presentations and FDA approvals.</p> <p><strong>Johnson &amp; Johnson </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>)&#39;s Janssen unit received an FDA nod for label expansion for its prostate cancer drug Erleada, and <strong>Eisai Co., Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/esaly#OTC">ESALY</a>)&#39;s Lenvantinib in combination with <strong> Merck &amp; Co., Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>)&#39;s <a href="https://www.benzinga.com/general/biotech/19/05/13722540/mercks-keytruda-vs-bristol-myers-squibbs-opdivo-in-q1-and-beyond">Keytruda</a> was approved for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.</p> <p>Among the biotech IPOs, <strong>IGM Biosciences, Inc</strong>. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/igms#NASDAQ">IGMS</a>) made a <a href="https://www.benzinga.com/general/biotech/19/09/14442683/igm-biosciences-ipo-what-you-need-to-know">strong debut</a>, closing its first session with a gain of about 46% from its IPO price of $16.</p> <p>The following are&nbsp;key catalysts for&nbsp;biotech investors to keep an eye on in the unfolding week.</p> <h3>Conferences</h3> <ul> <li>2nd World Summit on Liver Cirrhosis and Hepatitis &ndash; Sept. 23-24&nbsp;in Tokyo</li> <li>11th Euro-Global Conference on Infectious Diseases &ndash; Sept. 23-24&nbsp;in London</li> <li>Ladenburg Thalmann 2019 Healthcare Conference &ndash; Sept. 24&nbsp;in New York</li> <li>15th World Conference on Cosmetic Dermatology &amp; Skin Diseases &ndash; Sept. 25-26&nbsp;in Lisbon</li> <li>World Cancer Research and Biomarkers Conference &ndash; Sept. 25-26&nbsp;in Toronto</li> <li>6th International Conference on Hypertension &amp; Healthcare &ndash; Sept. 26-28&nbsp;in London</li> <li>Cancer Therapy &amp; Biomarkers - Sept. 27-28&nbsp;in Lisbon</li> <li>6th European Rett Syndrome Conference &ndash; Sept. 27-28&nbsp;in Tampere</li> <li>European Society for Medical Oncology 2019 Conference &ndash; Sept. 27- Oct. 1 ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/19/09/14460216/the-week-ahead-in-biotech-spotlight-on-esmo-conference alt=The Week Ahead In Biotech: Spotlight On ESMO Conference>Full story available on Benzinga.com</a></p> ABBV ALRN AMGN ARAV ASLN AVXL AZN Biotech CALA CKPT Earnings ESALY ESMO European Society for Medical Oncology GNCA GSK GTHX IBB IGMS IMMU INCY JNJ MRK News NVS PFE RHHBY RYTM SGEN TROV URGN XBI ZLAB ZYME Health Care Previews FDA Events Top Stories Trading Ideas General XBI US78464A8707 AMGN US0311621009 IBB US4642875565 IMMU US4529071080 INCY US45337C1027 SGEN US8125781026 AZN US0463531089 GSK US37733W1053 JNJ US4781601046 MRK US58933Y1055 NVS US66987V1098 PFE US7170811035 RHHBY US7711951043 AVXL ALRN TROV ESALY ABBV GNCA CALA RYTM CKPT ZYME URGN GTHX ZLAB ASLN ARAV IGMS News Earnings Biotech Health Care Previews FDA Events Top Stories Trading Ideas General Benzinga Sun, 22 Sep 2019 20:22:17 +0000 Shanthi Rexaline 14460216 at https://www.benzinga.com Syracuse Autism Conference with Dr. Temple Grandin - November 21, 2019 https://www.benzinga.com/pressreleases/19/09/r14469135/syracuse-autism-conference-with-dr-temple-grandin-november-21-2019 <p>Future Horizons will be hosting the Syracuse Autism Conference with Dr. Temple Grandin - November 21, 2019.</p> <p>Syracuse, NY, September 22, 2019 --(<a rel="nofollow" href="https://www.pr.com/" rel="nofollow">PR.com</a>)-- Join Dr. Temple Grandin and two great speakers for this special event in Syracuse, NY on November 21, 2019. This conference will include special appearances by Paula Aquilla, an occupational therapist, and Nick Maley, renowned worldwide as &#8220;That Yoda Guy.&#8221;</p> <p>Dr. Temple Grandin has served as an inspiration and a role model to hundreds of thousands of ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/r14469135/syracuse-autism-conference-with-dr-temple-grandin-november-21-2019 alt=Syracuse Autism Conference with Dr. Temple Grandin - November 21, 2019>Full story available on Benzinga.com</a></p> Arts & Entertainment lifestyle News Education Health Care Press Releases News Education Health Care Press Releases Benzinga Sun, 22 Sep 2019 07:00:00 +0000 PR.com 14469135 at https://www.benzinga.com Healing the Trauma Within, Women's Empowerment Summit https://www.benzinga.com/pressreleases/19/09/r14468855/healing-the-trauma-within-womens-empowerment-summit <p>15 Daring Women Share Their Methods to Move from Victim to Victorious.</p> <p>Atlanta, GA, September 21, 2019 --(<a rel="nofollow" href="https://www.pr.com/" rel="nofollow">PR.com</a>)-- There is a journey beyond being a victim, or even a survivor &#8211; it&#8217;s the journey to becoming a &#8220;thriver&#8221; &#8211; a healthy, happy person with a wonderful future ahead of them; someone who thrives in life.</p> <p>However, moving through the emotional pain and grief associated with trauma can make it hard to know how to get there. But there is hope.</p> <p>Daring Woman and Tracey Osborne ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/r14468855/healing-the-trauma-within-womens-empowerment-summit alt=Healing the Trauma Within, Women&#039;s Empowerment Summit>Full story available on Benzinga.com</a></p> Arts & Entertainment business lifestyle News Health Care Events Press Releases News Health Care Events Press Releases Benzinga Sat, 21 Sep 2019 07:00:00 +0000 PR.com 14468855 at https://www.benzinga.com Swedish Medical Center Receives Healthgrades 2019 Gynecologic Surgery Excellence Award™ for the Fourth Year in a Row https://www.benzinga.com/pressreleases/19/09/r14468853/swedish-medical-center-receives-healthgrades-2019-gynecologic-surgery-excellence-award-for-the-fou <p>Hospital recognized for superior clinical outcomes in gynecologic surgery.</p> <p>Englewood, CO, September 21, 2019 --(<a rel="nofollow" href="https://www.pr.com/" rel="nofollow">PR.com</a>)-- Swedish Medical Center is now a 2019 Gynecologic Surgery Excellence Award&#8482; recipient as recognized by Healthgrades, the leading online resource for information about physicians and hospitals. This is the fourth year in a row the hospital has been recognized with this award that places Swedish among a select group of hospitals - in the top 10 percent of all hospitals evaluated for providing outstanding quality outcomes in gynecologic surgery.</p> <p>&#8220;Our team of physicians, nurses and staff strive to ensure high quality, compassionate care to the women in our community,&#8221; said Christina Merritt, administrative director of women&#8217;s services at Swedish Medical Center. &#8220;It is a testament to our entire team to be nationally recognized by Healthgrades among such an elite group ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/r14468853/swedish-medical-center-receives-healthgrades-2019-gynecologic-surgery-excellence-award-for-the-fou alt=Swedish Medical Center Receives Healthgrades 2019 Gynecologic Surgery Excellence Award™ for the Fourth Year in a Row>Full story available on Benzinga.com</a></p> lifestyle marketing News Health Care Press Releases News Health Care Press Releases Benzinga Sat, 21 Sep 2019 07:00:00 +0000 PR.com 14468853 at https://www.benzinga.com Post Holdings Active Nutrition Business to be Named BellRing Brands; BellRing Brands Files Registration Statement for Proposed Initial Public Offering https://www.benzinga.com/pressreleases/19/09/g14467581/post-holdings-active-nutrition-business-to-be-named-bellring-brands-bellring-brands-files-registra <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>ST. LOUIS, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE" rel="nofollow">POST</a>) ("Post") announced that its active nutrition business will be named BellRing Brands, Inc. ("BellRing") following the completion of the previously announced proposed initial public offering ("IPO") of approximately 20% of its ownership.<br /></p> <p>Post also announced that BellRing has publicly filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") related to BellRing&#039;s proposed IPO of its Class A common stock. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The IPO is expected to be completed in the fall of 2019, subject to market and other conditions. BellRing has applied for its Class A common stock to be listed on the New York Stock Exchange under the symbol "BRBR".</p> <p>Morgan Stanley &amp; Co. LLC, Citigroup, J.P. Morgan Securities LLC and Goldman Sachs &amp; Co. LLC are acting as the lead bookrunning managers for the proposed offering. BofA Merrill Lynch, Barclays Capital Inc., BMO Capital Markets Corp., Credit Suisse Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus &amp; Company, Incorporated, SunTrust Robinson Humphrey, Inc. and Wells Fargo Securities, LLC are acting as bookrunning managers. HSBC Securities (USA) Inc., Nomura Securities International, Inc., PNC Capital Markets LLC, Rabo Securities USA, Inc. and UBS Securities LLC are acting as co-managers for the proposed offering.</p> <p>This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014; Citigroup Global Markets Inc., c/o Broadridge Financial ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14467581/post-holdings-active-nutrition-business-to-be-named-bellring-brands-bellring-brands-files-registra alt=Post Holdings Active Nutrition Business to be Named BellRing Brands; BellRing Brands Files Registration Statement for Proposed Initial Public Offering>Full story available on Benzinga.com</a></p> News POST Health Care Restaurants IPOs Press Releases General POST News Health Care Restaurants IPOs Press Releases General Benzinga Fri, 20 Sep 2019 20:21:01 +0000 Globe Newswire 14467581 at https://www.benzinga.com This Study Looks At How Canadians Use Cannabis For Health And Wellness https://www.benzinga.com/markets/cannabis/19/09/14452239/this-study-looks-at-how-canadians-use-cannabis-for-health-and-wellness <p>The results of Vivintel&rsquo;s latest study &ldquo;The Canadian Cannabis Study: Post-legalization Usage &amp; Opinions&rdquo; are in. The report looks at how Canadians are using cannabis for health and wellness.</p> <p>Here are the top three conclusions from the study:</p> <ul> <li>In Canada, there is a high rate of self-prescription: 71% (nearly 1.9 million) of Canadians using cannabis for medicinal reasons did not have a prescription from a medical professional.</li> <li>For a vast majority of Canadians who used cannabis as a remedy, treatment or therapy (82%, or over 2 million), the plant was &quot;more&quot; or &quot;somewhat more&quot; effective than modern medicine.</li> <li>There is a huge gap in the use of cannabis across many ailments, and age is a noticeable factor in determining which medical condition cannabis is being ...</li></ul><p><a href=https://www.benzinga.com/markets/cannabis/19/09/14452239/this-study-looks-at-how-canadians-use-cannabis-for-health-and-wellness alt=This Study Looks At How Canadians Use Cannabis For Health And Wellness>Full story available on Benzinga.com</a></p> Canada Cannabis medical marijuana Rahul Sethi Vivintel Health Care Crowdsourcing Markets General Cannabis Health Care Crowdsourcing Markets General Benzinga Fri, 20 Sep 2019 16:45:11 +0000 Javier Hasse 14452239 at https://www.benzinga.com American Oncology Network Expands Pathology Laboratory https://www.benzinga.com/pressreleases/19/09/g14465246/american-oncology-network-expands-pathology-laboratory <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Fort Myers, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Complete, accurate and timely pathology reports are critical to cancer diagnosis and treatment.  While cancer patients rarely, if ever, interact with the skilled physicians who evaluate their cells and tissues, pathologists are integral members of the cancer care team.  To serve its growing network of community-based oncology practices, <a href="https://www.globenewswire.com/Tracker?data=2Z1p8jnwWhWu2D-JxdA88JCGgdIeRD8m7KsCTqiG6uI4kp9SdhUeWUvXNynadgbiA6TTg6fs16vFAbIsoXy-udkm_aTuA2eVkpxVeaJTM1afYXn4smniUZ_I84sWawMB" rel="nofollow" target="_blank" rel="nofollow">American Oncology Network, LLC (AON)</a> has doubled the size of its centralized Pathology Laboratory. A ribbon cutting ceremony is scheduled this month at the newly constructed facility located in Fort Myers, Florida.</p> <p>The AON Pathology Laboratory currently serves nearly 50 physicians in seven states with a testing menu that includes flow cytometry, histology and immunohistochemistry, cytogenetics, FISH (florescence in-situ hybridization) and central lab services.  While the type of testing performed at the lab does not depart much from that provided by in-hospital or reference labs, AON&#039;s centralized approach yields numerous advantages to oncologists and their patients.</p> <p>"Our lab and our staff are seamlessly integrated into daily patient care and we maintain highly personal communication with the oncologists we serve," said Dr. Ryan Olson, medical director of AON&#039;s Pathology Laboratory.</p> <p>"The advantage of having direct access to patient health information through AON&#039;s state-of-the-art electronic medical records system cannot be overstated," he added. "Because we can see a patient&#039;s complete health history, we know exactly why the testing has been ordered and what questions the oncologist wants answered."  When a pathologist discovers that additional testing of a specimen is necessary to obtain a more precise diagnosis, they are often able to make the ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14465246/american-oncology-network-expands-pathology-laboratory alt=American Oncology Network Expands Pathology Laboratory>Full story available on Benzinga.com</a></p> News Health Care Press Releases General News Health Care Press Releases General Benzinga Fri, 20 Sep 2019 14:53:53 +0000 Globe Newswire 14465246 at https://www.benzinga.com Profound Medical Announces Closing of Offerings https://www.benzinga.com/pressreleases/19/09/g14464355/profound-medical-announces-closing-of-offerings <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="center"><strong>NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES</strong></p> <p align="justify">TORONTO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PRN#TSX" rel="nofollow">PRN</a>, OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/PRFMF#OTCQX" rel="nofollow">PRFMF</a>) ("<strong>Profound</strong>" or the "<strong>Company</strong>") is pleased to announce that it has closed its previously-announced offering of units of the Company (the "<strong>Units</strong>") in all provinces of Canada, other than Quebec (the "<strong>Offering</strong>") and in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the "<strong>Concurrent U.S. Private Offering</strong>"), including the full exercise of the over-allotment option. An aggregate of 10,454,546 Units were sold at a price of $1.10 per Unit for aggregate gross proceeds of $11,500,001.60.<br /></p> <p align="justify">Each Unit consists of one common share (a "<strong>Common Share</strong>") and one-half of one common share purchase warrant (each whole common share purchase warrant, a "<strong>Warrant</strong>") of the Company. Each Warrant is exercisable to acquire one common share of the Company (a "<strong>Warrant Share</strong>") until September 20, 2021 at an exercise price of $1.55 per Warrant Share, subject to adjustment in certain events.</p> <p align="justify">The Offering was made pursuant to a prospectus supplement (the "<strong>Prospectus Supplement"</strong>) dated September 13, 2019  to the Company&#039;s short form base shelf prospectus dated September 19, 2018 (the "<strong>Base Shelf Prospectus</strong>"). Copies of the Prospectus Supplement and Base Shelf Prospectus are available on the Company&#039;s SEDAR profile at <a href="https://www.globenewswire.com/Tracker?data=xrPQVn7NNt8K85s7xcZNOF9O5GD51BEPi5qUM_t05KrcUvlZbmR0GdbtDIqJPuR6x5QGjtCCvSmQC4IE3xrX1A==" rel="nofollow" target="_blank" rel="nofollow">www.sedar.com</a>.  </p> <p align="justify">The Concurrent U.S. Private Offering was made solely pursuant to a confidential U.S. Private Placement Memorandum (the "<strong>U.S. PPM</strong>") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the "<strong>U.S. Securities Ac</strong>t"), and Units sold in the Offering were made solely pursuant to the Prospectus Supplement to certain non-U.S. persons in offshore ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14464355/profound-medical-announces-closing-of-offerings alt=Profound Medical Announces Closing of Offerings>Full story available on Benzinga.com</a></p> PRFMF TSX:PRN Health Care Markets Press Releases PRFMF TSX:PRN Health Care Markets Press Releases Benzinga Fri, 20 Sep 2019 13:13:55 +0000 Globe Newswire 14464355 at https://www.benzinga.com Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference https://www.benzinga.com/pressreleases/19/09/g14464015/anchiano-therapeutics-to-present-at-the-ladenburg-thalmann-healthcare-conference <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANCN#NASDAQ" rel="nofollow">ANCN</a>) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, being held September 24, 2019 at the Sofitel in New York City.<br /></p> <table style="border-collapse: collapse; font-size: 15px; width:100%; border-collapse:collapse ;"> <tr> <td colspan="2" style="vertical-align: top ; "><strong><u>Anchiano Therapeutics Presentation Details</u></strong></td> </tr> <tr> <td style="max-width:15%; width:15%; min-width:15%;;vertical-align: top ; ">Conference:</td> <td style="max-width:85%; width:85%; min-width:85%;;vertical-align: top ; ">Ladenburg Thalmann Healthcare Conference </td> </tr> <tr> <td ...</tr></table><p><a href=https://www.benzinga.com/pressreleases/19/09/g14464015/anchiano-therapeutics-to-present-at-the-ladenburg-thalmann-healthcare-conference alt=Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference>Full story available on Benzinga.com</a></p> ANCN News Health Care Press Releases ANCN News Health Care Press Releases Benzinga Fri, 20 Sep 2019 12:30:00 +0000 Globe Newswire 14464015 at https://www.benzinga.com Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson's Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress https://www.benzinga.com/pressreleases/19/09/g14463825/adamas-announces-new-safety-and-efficacy-data-for-gocovri-in-parkinsons-disease-patients-with-dysk <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMS#NASDAQ" rel="nofollow">ADMS</a>), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, announced today the presentation of new data on GOCOVRI<sup>®</sup> (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson&#39;s disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2019 International Congress, September 22-26, 2019 in Nice, France. The poster presentations will highlight data derived from the GOCOVRI development program and post-marketing pharmacovigilance surveillance.<br /></p> <p>"Adamas&#039; purpose is to significantly improve the lives of people affected by neurological diseases, and we remain committed to the presentation of GOCOVRI data to provide further information to support robust clinical discussions," said Rajiv Patni, MD, Chief Medical Officer at Adamas. "Our goal is to ensure that neurologists understand how GOCOVRI may be an option for their Parkinson&#039;s disease patients with dyskinesia on dopaminergic therapies by providing them with a treatment that may increase functional ON time by decreasing both dyskinesia and OFF."</p> <p>The five posters will be part of the "Clinical Trials, Pharmacology and Treatment" session on Monday, September 23, 2019, from 1:45-3:15pm Central European Time (CET). Details of the poster presentations are as follows:</p> <table style="border-collapse: collapse; font-size: 15px; width:100%; border-collapse:collapse ;"> <tr> <td style="max-width:5%; width:5%; min-width:5%;"> </td> <td style="max-width:95%; width:95%; min-width:95%;"><em>Poster 106: "The Effect of GOCOVRI on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program"</em><br />Lead Author: Dr. Robert Hauser, University of South Florida</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td><em>Poster 107: "Analysis of the Shape of the GOCOVRI Steady-state PK Profile: Implications for an Extended Release Product"</em><br />Lead Author: Dr. Robert Hauser, University of South Florida</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td><em>Poster 115: "GOCOVRI Dose Adjustment in Elderly Parkinson&#039;s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model"</em><br />Lead Author: Dr. Stuart Isaacson, Parkinson&#39;s Disease &amp; Movement Disorders Center of Boca Raton</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td><em>Poster 171: "The Efficacy and Safety of GOCOVRI Based on Age: Special Population Analyses of a Phase 3 Study Program"</em><br />Lead Author: Dr. Rajesh Pahwa, University of Kansas Medical Center</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td><em>Poster 213: "Safety of GOCOVRI in Clinical Practice: One-Year Post-Launch Pharmacovigilance Data"</em><br />Lead Author: Dr. Caroline Tanner, University of California, San Francisco</td> </tr> </table> <p align="justify"><strong>About Parkinson&#039;s Disease, OFF and Dyskinesia</strong></p> <p>Parkinson&#039;s Disease (PD) is a progressive, neurodegenerative disorder caused by a dysregulation of neurotransmitter signaling, ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14463825/adamas-announces-new-safety-and-efficacy-data-for-gocovri-in-parkinsons-disease-patients-with-dysk alt=Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson&#039;s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress>Full story available on Benzinga.com</a></p> ADMS Health Care Press Releases ADMS Health Care Press Releases Benzinga Fri, 20 Sep 2019 12:00:00 +0000 Globe Newswire 14463825 at https://www.benzinga.com Lucent Botanicals' Designer CBD Mints Now Available on Health and Wellness Portal VitaBeauti.Com https://www.benzinga.com/pressreleases/19/09/g14462887/lucent-botanicals-designer-cbd-mints-now-available-on-health-and-wellness-portal-vitabeauti-com <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>OAKLAND, CA, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Designer CBD mints are now available on <a href="https://www.globenewswire.com/Tracker?data=qnUMOoUb0fgpTusCyWPUvvI6QmRmj3w-1MUaX1fCfggSR81xB8ZP7ZJ7CJyW1DIYhdJ4nOlxwumPJo9X8l6pJKWyNfEKIpx3XcBmWPvReoo=" rel="nofollow" target="_blank" rel="nofollow">vitabeauti.com</a>, a health and wellness website. </p> <p>Lucent Botanicals, the company behind these custom-designed CBD mints, decided this year to expand their distribution network in the United States. Making the CBD mints available on <a href="https://www.globenewswire.com/Tracker?data=qnUMOoUb0fgpTusCyWPUvuVd6oFBdwJhaaDeQbEcxoMO4gTVC3SMpMbq8IgAFFDWHNcCqT5Z8fEI2Kx8hz84U9sbmmbw1IqOg1mdmFZOPIU=" rel="nofollow" target="_blank" rel="nofollow">vitabeauti.com</a> is a step toward achieving that goal.</p> <p>"We are pleased to have seven CBD mints on sale at <a href="https://www.globenewswire.com/Tracker?data=qnUMOoUb0fgpTusCyWPUvmPB1BRyUwS_M_O9-lWOluC-EdWnlTZ1R4SfblN7zkk8YwFgcEmn6cvQtKo1PpCTfvme0zuMUchvK5asJHBQNdQ=" rel="nofollow" target="_blank" rel="nofollow">vitabeauti.com</a>. These CBD mints are for people who need energy, improved focus, inflammation relief, a mood lift, pain relief, calm, and sleep," said Chris Cooper, founder ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14462887/lucent-botanicals-designer-cbd-mints-now-available-on-health-and-wellness-portal-vitabeauti-com alt=Lucent Botanicals&#039; Designer CBD Mints Now Available on Health and Wellness Portal VitaBeauti.Com>Full story available on Benzinga.com</a></p> lifestyle Health Care Press Releases General Health Care Press Releases General Benzinga Fri, 20 Sep 2019 07:06:00 +0000 Globe Newswire 14462887 at https://www.benzinga.com Nutritional Products International to Attend 23rd Americas Food and Beverage Show & Conference in Miami Beach https://www.benzinga.com/pressreleases/19/09/g14462886/nutritional-products-international-to-attend-23rd-americas-food-and-beverage-show-conference-in-mi <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>BOCA RATON, FL, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Nutritional Products International will participate in the <a href="https://www.globenewswire.com/Tracker?data=rcf03Unuy66MusY7ZeW31PBaEEm6KkbxZQsxVxs5OvyWBhfqFYuFPevD780bJUvrxSBbNFJQWUNLVh2EJ1Ab5C2dtA6_ST21DKa2ti7fJoOOcrqisQbaoGPoytcdcwQffoi1rcEyiAxDw18QYz94-3R05NH46s761GQfoloS6To=" rel="nofollow" target="_blank" rel="nofollow">23<sup>rd</sup> Americas Food and Beverages Show and Conference</a> Sept. 23-24 at the Miami Beach Convention Center. </p> <p>The networking show brings together the largest selection of food and beverage companies from the Americas. It is a one-stop marketplace that brings all segments of the food and beverage industry together to expand sales opportunities. The show will have more than 11,000 decision-making buyers and more than 450 exhibitors.</p> <p>NPI, a global brand marketing company, works with domestic and international food and beverage companies to expand into or enter the U.S. market.</p> <p>"We ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14462886/nutritional-products-international-to-attend-23rd-americas-food-and-beverage-show-conference-in-mi alt=Nutritional Products International to Attend 23rd Americas Food and Beverage Show &amp; Conference in Miami Beach>Full story available on Benzinga.com</a></p> Health Care Restaurants Press Releases General Health Care Restaurants Press Releases General Benzinga Fri, 20 Sep 2019 07:06:00 +0000 Globe Newswire 14462886 at https://www.benzinga.com NIX United Opens an Office in Saint Petersburg, FL https://www.benzinga.com/pressreleases/19/09/r14462875/nix-united-opens-an-office-in-saint-petersburg-fl <p>A large tech service provider, NIX United, announces the opening of a U.S. office. From 1994 and onward NIX has been actively operating in the U.S., and is now ready to officially open the doors of its office in Florida for every guest.</p> <p>Saint Petersburg, FL, September 20, 2019 --(<a rel="nofollow" href="https://www.pr.com/" rel="nofollow">PR.com</a>)-- The company, with 25-years of experience, specializes in software development for healthcare, insurance, e-commerce, e-learning, and other domains. A team of 2,000 will satisfy the needs of modern business and address tech challenges to take your enterprise to the next level. They professionally deal with both cutting-edge technologies (Blockchain, VR/AR, IoT, DevOps, Data Science) and traditional ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/r14462875/nix-united-opens-an-office-in-saint-petersburg-fl alt=NIX United Opens an Office in Saint Petersburg, FL>Full story available on Benzinga.com</a></p> business insurance News Education Health Care Tech Press Releases News Education Health Care Tech Press Releases Benzinga Fri, 20 Sep 2019 07:00:00 +0000 PR.com 14462875 at https://www.benzinga.com Aspero Medical announces James Willett as CEO https://www.benzinga.com/pressreleases/19/09/g14461967/aspero-medical-announces-james-willett-as-ceo <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Boulder, Colorado, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Aspero Medical, University of Colorado Boulder spinoff and <a href="https://www.globenewswire.com/Tracker?data=izh0m8tbpGQ6mRfycn6uX4BNqHgLjqyOHh3SVoM_C5N0kSFTmdfbLEwNhIV6eNwsPCdvRw1xWXJMDNmFdfqHdA==" rel="nofollow" target="_blank" rel="nofollow">Innosphere</a> client company, announced today that James Willett has been appointed President and Chief Executive Officer of the medical device startup company that focuses on improving gastrointestinal (GI) balloon endoscopy procedures. Founded in 2018, Aspero Medical has developed an innovative product called the AP<sup>TM </sup>Balloon Overtube that will be used to assist with the diagnosis of GI disease which effects over 70 million patients annually in the United States.</p> <p>"As Aspero Medical prepares to move forward with final development and manufacturing of the company&#039;s initial product line, we sought a leader who had direct experience in the medical device industry and a proven track record of commercializing innovative technologies." Said Mark Rentschler, Aspero Medical Chief Technology Officer.  "Jim brings a diverse background across specialties in the medical device ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14461967/aspero-medical-announces-james-willett-as-ceo alt=Aspero Medical announces James Willett as CEO>Full story available on Benzinga.com</a></p> Licensing News Health Care Management Press Releases News Health Care Management Press Releases Benzinga Thu, 19 Sep 2019 21:26:19 +0000 Globe Newswire 14461967 at https://www.benzinga.com HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock https://www.benzinga.com/pressreleases/19/09/g14461076/htg-molecular-diagnostics-announces-proposed-public-offering-of-common-stock <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">TUCSON, Ariz., Sept. 19, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTGM#NASDAQ" rel="nofollow">HTGM</a>) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the shares are being offered by HTG. In addition, HTG expects to grant the underwriter for the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.<br /></p> <p>Cantor Fitzgerald &amp; Co. is acting as the sole book-running manager for the offering.</p> <p>The shares of common stock described above are being offered by HTG pursuant to a shelf registration statement filed by HTG with the Securities and Exchange Commission (SEC) that was declared effective on February 11, 2019. A preliminary prospectus supplement related ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/g14461076/htg-molecular-diagnostics-announces-proposed-public-offering-of-common-stock alt=HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock>Full story available on Benzinga.com</a></p> HTGM Health Care Markets Press Releases HTGM Health Care Markets Press Releases Benzinga Thu, 19 Sep 2019 20:01:00 +0000 Globe Newswire 14461076 at https://www.benzinga.com